Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review

Weight-Loss Pill Stopped After Trial Setback

Translate to Spanish or other 102 languages!

Pfizer Inc. announced today that it will discontinue the development of danuglipron (PF-06882961), an oral GLP-1 receptor agonist under investigation for chronic weight management. The decision follows a comprehensive review of clinical trial data, including a case of potential drug-induced liver injury. Image; Pfizer image source: János Korom Dr. >17 Million views from Wien, Austria, CC BY-SA 2.0 https://creativecommons.org/licenses/by-sa/2.0, via Wikimedia Commons. medication for illustration purposes
- Advertisement -

Mega Doctor News

NEW YORK — Pfizer Inc. announced today that it will discontinue the development of danuglipron (PF-06882961), an oral GLP-1 receptor agonist under investigation for chronic weight management. The decision follows a comprehensive review of clinical trial data, including a case of potential drug-induced liver injury.

The company’s dose-optimization studies (NCT06567327 and NCT06568731) had achieved key pharmacokinetic goals and identified a once-daily formulation with the potential for competitive efficacy and tolerability in Phase 3 trials. However, among more than 1,400 participants, one individual experienced asymptomatic liver enzyme elevations consistent with potential liver injury, which resolved after discontinuation of the drug.

- Advertisement -
Dr. Chris Boshoff. Image: LinkedIN

While the overall safety profile was in line with other approved drugs in the GLP-1 class, Pfizer opted to stop development after evaluating the totality of data and receiving input from regulatory authorities.

“Cardiovascular and metabolic diseases, including obesity, remain important areas of unmet medical need,” said Dr. Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer. “We plan to continue advancing a pipeline of investigational treatments, including our oral GIPR antagonist candidate and other earlier-stage obesity programs.”

Pfizer intends to present findings from the Danuglipron clinical program at a scientific forum or submit them for publication in a peer-reviewed journal. The move reflects Pfizer’s continued commitment to innovation in the obesity and metabolic health space despite challenges in drug development. Source: Pfizer.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

AMA Advises Patients to Check with Doctors on Web Advice

The internet offers no shortage of health advice. But with misleading medical claims spread across social media, search engines, and AI platforms, finding trustworthy answers can be a challenge. 

FDA Authorizes Focused Ultrasound Treatment for Varicose Veins

Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
- Advertisement -